Analysts Expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Will Post Quarterly Sales of $38.56 Million

Equities research analysts forecast that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post $38.56 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings. The lowest sales estimate is $33.85 million and the highest is $42.80 million. Ultragenyx Pharmaceutical reported sales of $18.17 million during the same quarter last year, which indicates a positive year over year growth rate of 112.2%. The business is expected to report its next earnings report on Monday, May 4th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $181.56 million for the current financial year, with estimates ranging from $149.10 million to $201.90 million. For the next year, analysts anticipate that the firm will report sales of $291.79 million, with estimates ranging from $201.90 million to $345.13 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.61) by ($0.01). Ultragenyx Pharmaceutical had a negative return on equity of 49.81% and a negative net margin of 388.30%. The firm had revenue of $35.59 million for the quarter, compared to analysts’ expectations of $32.31 million.

RARE has been the subject of several recent research reports. Morgan Stanley increased their price objective on Ultragenyx Pharmaceutical from $73.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. SunTrust Banks reiterated a “buy” rating and set a $80.00 price objective (up from $75.00) on shares of Ultragenyx Pharmaceutical in a report on Friday, January 10th. Raymond James lowered Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a report on Thursday, January 2nd. Piper Jaffray Companies reiterated a “buy” rating and set a $70.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, December 18th. Finally, Wedbush increased their price objective on Ultragenyx Pharmaceutical from $71.00 to $75.00 and gave the stock an “outperform” rating in a report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $74.92.

Shares of NASDAQ:RARE traded up $0.45 during midday trading on Friday, hitting $61.55. 326,935 shares of the stock were exchanged, compared to its average volume of 573,631. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.64 and a current ratio of 6.79. Ultragenyx Pharmaceutical has a 52-week low of $35.41 and a 52-week high of $74.50. The business’s fifty day simple moving average is $55.70 and its two-hundred day simple moving average is $47.86. The company has a market capitalization of $3.54 billion, a PE ratio of -8.64 and a beta of 2.35.

In other Ultragenyx Pharmaceutical news, SVP Theodore Alan Huizenga sold 1,000 shares of the stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $61.00, for a total transaction of $61,000.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Capital World Investors grew its position in shares of Ultragenyx Pharmaceutical by 36.5% in the fourth quarter. Capital World Investors now owns 3,237,295 shares of the biopharmaceutical company’s stock valued at $138,265,000 after purchasing an additional 865,865 shares during the last quarter. Orbimed Advisors LLC grew its position in shares of Ultragenyx Pharmaceutical by 948.0% in the third quarter. Orbimed Advisors LLC now owns 834,313 shares of the biopharmaceutical company’s stock valued at $35,692,000 after purchasing an additional 754,706 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Ultragenyx Pharmaceutical by 154.8% in the fourth quarter. Franklin Resources Inc. now owns 370,650 shares of the biopharmaceutical company’s stock valued at $15,830,000 after purchasing an additional 225,200 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Ultragenyx Pharmaceutical by 15.8% in the fourth quarter. Alliancebernstein L.P. now owns 1,547,393 shares of the biopharmaceutical company’s stock valued at $66,089,000 after purchasing an additional 211,635 shares during the last quarter. Finally, EcoR1 Capital LLC grew its position in shares of Ultragenyx Pharmaceutical by 324.9% in the fourth quarter. EcoR1 Capital LLC now owns 261,554 shares of the biopharmaceutical company’s stock valued at $11,171,000 after purchasing an additional 200,000 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Further Reading: FinTech

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.